Key papers, reviewed

The updated framework expands the original nine hallmarks of aging to twelve, adding disabled macroautophagy, chronic inflammation, and dysbiosis. The hallmarks are organized into primary, antagonistic, and integrative categories with explicit cross-talk.

• 01Twelve hallmarks now cover molecular through systemic levels of aging.
• 02Inflammaging is elevated to a hallmark in its own right.
• 03Hallmarks are highly interconnected — single-target interventions rarely act on one in isolation.

The framework remains descriptive rather than strictly causal. Several hallmarks may be downstream readouts (epigenetic alterations) rather than drivers. Useful as a teaching scaffold and target-discovery lens, less so as a strict mechanistic ranking.

Foundational paper articulating the geroscience hypothesis: that aging is the dominant risk factor for most chronic diseases and that intervening in aging biology can simultaneously delay multiple end-organ diseases.

• 01Single-disease research models underestimate the upstream contribution of aging.
• 02Geroprotectors should be evaluated against composite multimorbidity endpoints.
• 03Established the policy and regulatory rationale that motivates TAME and similar trials.

Mostly aspirational. Translation from preclinical lifespan results to human composite endpoints remains the field's central unsolved problem.

First demonstration that rapamycin, started in mid-to-late life, extends both median and maximum lifespan in genetically diverse mice across three independent sites.

• 01Lifespan extension reproducible across ITP sites.
• 02Effect observed when treatment started at age equivalent to ~60 human years.
• 03Established rapamycin as the most reproducible pharmacologic geroprotector in mammals.

Mouse pharmacokinetics differ substantially from humans. Dose, schedule, and chronic-vs-intermittent regimens for translation remain unsettled. No completed human mortality-endpoint trial.

Low-dose RAD001 (everolimus) improved influenza vaccine responses in adults ≥65 with an acceptable safety profile, providing proof-of-concept for mTOR inhibition as immune rejuvenation in humans.

• 01Improved seroconversion to influenza vaccine strains.
• 02Acceptable adverse-event profile at the doses tested.
• 03Provided the regulatory and mechanistic basis for subsequent mTOR-inhibitor healthspan trials.

Surrogate immunologic endpoint, not clinical outcome. Findings have not translated directly to off-label rapamycin dosing schedules used in private longevity clinics.

Short-course dasatinib + quercetin in adults with idiopathic pulmonary fibrosis improved 6-minute walk distance and several physical-function measures over 5 days of intermittent dosing.

• 01First human trial to apply hit-and-run senolytic dosing in disease.
• 02Functional improvements on short follow-up.
• 03No control arm; small sample.

Open-label, single-arm, very small sample. Frequently cited beyond its evidentiary weight. Larger randomized trials are required and ongoing.

In adults with overweight or obesity and pre-existing cardiovascular disease, weekly semaglutide reduced major adverse cardiovascular events by ~20% vs placebo over a mean follow-up of about three years.

• 01First cardiovascular-outcome benefit demonstrated for a weight-loss therapy in non-diabetic patients.
• 02Effect independent of weight loss magnitude in subgroup analyses.
• 03Reframed obesity pharmacotherapy as cardiovascular and healthspan therapy.

Trial population enriched for established CVD; generalizability to lower-risk healthy adults uncertain. Long-term safety beyond several years still accumulating. Discontinuation drives rebound.

Metformin attenuated training-induced improvements in cardiorespiratory fitness and skeletal muscle mitochondrial respiration in older adults compared with placebo.

• 01Blunted gains in VO2peak.
• 02Reduced mitochondrial respiration adaptations.
• 03Provides a concrete counter-argument to indiscriminate off-label metformin use.

Moderate sample; healthy older adults. Whether the effect generalizes to lower training volumes or different populations is unclear.

Higher cardiorespiratory fitness was associated with lower all-cause mortality across all age groups and sexes, with no observed upper limit to the benefit of fitness.

• 01Low fitness conferred mortality risk comparable to or greater than smoking and diabetes.
• 02No plateau of benefit observed at the highest fitness levels.
• 03Reinforces fitness as a vital sign.

Observational design; residual confounding likely. Causal inference relies on convergence with interventional trials of exercise.

Introduced the first multi-tissue epigenetic clock predicting chronological age from DNA methylation at 353 CpG sites, opening the field of measurable biological age.

• 01Strong correlation with chronological age across tissues.
• 02Deviation between epigenetic and chronological age associates with mortality in subsequent work.
• 03Catalyzed downstream clocks: PhenoAge, GrimAge, DunedinPACE.

First-generation clock — trained on chronological age, not mortality. Better suited for population research than individual clinical decisions.